Does the media prefer IMVT or STOK?

In the previous week, Immunovant had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 13 mentions for Immunovant and 8 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Immunovant's score of 0.46 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor STOK or RYTM?

In the previous week, Stoke Therapeutics had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Stoke Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Stoke Therapeutics' score of 1.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MIRM or STOK?

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 8 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Mirum Pharmaceuticals' score of 0.78 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SYRE or STOK?

In the previous week, Stoke Therapeutics had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Stoke Therapeutics and 6 mentions for Spyre Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Spyre Therapeutics' score of 1.03 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is STOK or LNTH more profitable?

Lantheus has a net margin of 18.05% compared to Stoke Therapeutics' net margin of -529.20%. Lantheus' return on equity of 29.32% beat Stoke Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Stoke Therapeutics -529.20% -48.84% -42.27% Lantheus 18.05% 29.32% 15.00%

Does the media refer more to STOK or LNTH?

In the previous week, Stoke Therapeutics had 3 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Stoke Therapeutics and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Stoke Therapeutics' score of 1.07 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Stoke Therapeutics (STOK) Competitors

$29.46 -1.92 (-6.12%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$29.47 +0.01 (+0.02%)

As of 08:53 AM Eastern

Compare

STOK vs. IMVT, RYTM, MIRM, SYRE, and LNTH

Should you buy Stoke Therapeutics stock or one of its competitors? MarketBeat compares Stoke Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Stoke Therapeutics include Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), Spyre Therapeutics (SYRE), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Stoke Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

In the previous week, Immunovant had 5 more articles in the media than Stoke Therapeutics. MarketBeat recorded 13 mentions for Immunovant and 8 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Immunovant's score of 0.46 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant currently has a consensus target price of $39.70, suggesting a potential upside of 2.58%. Stoke Therapeutics has a consensus target price of $42.00, suggesting a potential upside of 42.57%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Stoke Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A

Immunovant has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Summary

Stoke Therapeutics beats Immunovant on 12 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Stoke Therapeutics (NASDAQ:STOK) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Stoke Therapeutics' net margin of -529.20%. Stoke Therapeutics' return on equity of -48.84% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Stoke Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.88, meaning that its share price is 88% more volatile than the broader market.

Stoke Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Rhythm Pharmaceuticals	$189.76M	38.82	-$196.54M	-$3.13	N/A

Stoke Therapeutics currently has a consensus target price of $42.00, indicating a potential upside of 42.57%. Rhythm Pharmaceuticals has a consensus target price of $138.29, indicating a potential upside of 28.65%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Stoke Therapeutics is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Stoke Therapeutics had 5 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 8 mentions for Stoke Therapeutics and 3 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.14 beat Stoke Therapeutics' score of 1.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Stoke Therapeutics beats Rhythm Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Stoke Therapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Mirum Pharmaceuticals had 3 more articles in the media than Stoke Therapeutics. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 8 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Mirum Pharmaceuticals' score of 0.78 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals has a net margin of -140.24% compared to Stoke Therapeutics' net margin of -529.20%. Mirum Pharmaceuticals' return on equity of -11.28% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Stoke Therapeutics has lower revenue, but higher earnings than Mirum Pharmaceuticals. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	13.92	-$23.36M	-$13.61	N/A
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A

Mirum Pharmaceuticals has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Mirum Pharmaceuticals presently has a consensus price target of $143.40, indicating a potential upside of 20.46%. Stoke Therapeutics has a consensus price target of $42.00, indicating a potential upside of 42.57%. Given Stoke Therapeutics' higher possible upside, analysts plainly believe Stoke Therapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Mirum Pharmaceuticals beats Stoke Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Stoke Therapeutics compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Stoke Therapeutics (NASDAQ:STOK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

In the previous week, Stoke Therapeutics had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 8 mentions for Stoke Therapeutics and 6 mentions for Spyre Therapeutics. Stoke Therapeutics' average media sentiment score of 1.07 beat Spyre Therapeutics' score of 1.03 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stoke Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	$890K	9,261.37	-$155.20M	-$2.08	N/A
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -529.20%. Spyre Therapeutics' return on equity of -42.88% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Stoke Therapeutics	-529.20%	-48.84%	-42.27%

Spyre Therapeutics has a beta of 3.02, indicating that its stock price is 202% more volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Spyre Therapeutics presently has a consensus price target of $101.42, suggesting a potential upside of 8.20%. Stoke Therapeutics has a consensus price target of $42.00, suggesting a potential upside of 42.57%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Spyre Therapeutics beats Stoke Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Stoke Therapeutics compare to Lantheus?

Stoke Therapeutics (NASDAQ:STOK) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Stoke Therapeutics has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

Lantheus has higher revenue and earnings than Stoke Therapeutics. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42M	9.95	-$6.89M	-$2.81	N/A
Lantheus	$1.54B	4.45	$233.56M	$4.15	25.40

Lantheus has a net margin of 18.05% compared to Stoke Therapeutics' net margin of -529.20%. Lantheus' return on equity of 29.32% beat Stoke Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-529.20%	-48.84%	-42.27%
Lantheus	18.05%	29.32%	15.00%

99.1% of Lantheus shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Stoke Therapeutics currently has a consensus price target of $42.00, suggesting a potential upside of 42.57%. Lantheus has a consensus price target of $108.29, suggesting a potential upside of 2.75%. Given Stoke Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Stoke Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Stoke Therapeutics had 3 more articles in the media than Lantheus. MarketBeat recorded 8 mentions for Stoke Therapeutics and 5 mentions for Lantheus. Lantheus' average media sentiment score of 1.19 beat Stoke Therapeutics' score of 1.07 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stoke Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Stoke Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Stoke Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STOK vs. The Competition

Export

Metric	Stoke Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-10.48	20.85	27.11	24.26
Price / Sales	9.95	314.01	589.18	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.77	8.49	10.73	6.29
Net Income	-$6.89M	$23.83M	$3.58B	$330.66M
7 Day Performance	-10.78%	-3.56%	-2.11%	-1.35%
1 Month Performance	-1.21%	6.31%	3.27%	-0.64%
1 Year Performance	144.28%	48.30%	26.32%	19.08%

Stoke Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STOK Stoke Therapeutics	2.4463 of 5 stars	$29.46 -6.1%	$42.00 +42.6%	+148.4%	$1.95B	$184.42M	N/A	100	News Coverage Positive News Analyst Forecast
IMVT Immunovant	2.0853 of 5 stars	$38.60 -0.5%	$39.70 +2.8%	+113.5%	$7.96B	N/A	N/A	120
RYTM Rhythm Pharmaceuticals	3.2732 of 5 stars	$111.68 -2.2%	$136.13 +21.9%	+24.0%	$7.82B	$189.76M	N/A	140	Positive News
MIRM Mirum Pharmaceuticals	2.5495 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+126.1%	$7.66B	$521.31M	N/A	140
SYRE Spyre Therapeutics	2.0245 of 5 stars	$88.74 +2.4%	$95.83 +8.0%	+497.4%	$7.62B	$890K	N/A	73	Positive News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STOK) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stoke Therapeutics (STOK) Competitors

STOK vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Stoke Therapeutics compare to Immunovant?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Summary

How does Stoke Therapeutics compare to Mirum Pharmaceuticals?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Summary

How does Stoke Therapeutics compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Stoke Therapeutics (STOK) Competitors

STOK vs. IMVT, RYTM, MIRM, SYRE, and LNTH

How does Stoke Therapeutics compare to Immunovant?

Do institutionals & insiders hold more shares of IMVT or STOK?

Which has more risk and volatility, IMVT or STOK?

Does the media prefer IMVT or STOK?

Do analysts rate IMVT or STOK?

Which has higher earnings and valuation, IMVT or STOK?

Is IMVT or STOK more profitable?

Summary

How does Stoke Therapeutics compare to Rhythm Pharmaceuticals?

Is STOK or RYTM more profitable?

Which has more risk and volatility, STOK or RYTM?

Which has higher valuation & earnings, STOK or RYTM?

Do analysts rate STOK or RYTM?

Does the media favor STOK or RYTM?

Summary

How does Stoke Therapeutics compare to Mirum Pharmaceuticals?

Does the media favor MIRM or STOK?

Is MIRM or STOK more profitable?

Which has preferable valuation and earnings, MIRM or STOK?

Which has more volatility and risk, MIRM or STOK?

Do analysts recommend MIRM or STOK?

Summary

How does Stoke Therapeutics compare to Spyre Therapeutics?

Does the media refer more to SYRE or STOK?

Which has better earnings and valuation, SYRE or STOK?

Is SYRE or STOK more profitable?

Which has more risk & volatility, SYRE or STOK?

Do insiders and institutionals hold more shares of SYRE or STOK?

Do analysts prefer SYRE or STOK?

Summary

How does Stoke Therapeutics compare to Lantheus?

Which has more risk and volatility, STOK or LNTH?

Which has stronger earnings and valuation, STOK or LNTH?

Is STOK or LNTH more profitable?

Do institutionals and insiders hold more shares of STOK or LNTH?

Do analysts prefer STOK or LNTH?

Does the media refer more to STOK or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK vs. The Competition

Stoke Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools